

**REMARKS**

This paper is being filed under 37 CFR §1.312 and pursuant to 37 CFR §1.72 to amend the title and abstract of the invention in order to be as short and specific as possible to the invention claimed. This amendment (1) is needed for proper disclosure and protection of the invention and (2) requires no substantial amount of additional work on the part of the PTO. The amendment reflects the identification of the claimed subject matter, correction of which is proper for proper disclosure in the Title of the invention.

In addition, the Cross Reference to Related Applications section has been amended to delete reference to those provisional applications (U.S. provisional patent application 60/241,884, and U.S. provisional patent application 60/241,877, both of which were filed on October 20, 2000) upon which the claimed invention of the allowed claims no longer relies.

This paper is being filed timely as no extensions of time are required. In the event any additional extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.


Entry of the remarks made herein is respectfully requested.

June 28, 2005

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Kerri Pollard Schray  
Registration No. 47,066  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone – (617) 551-3676  
Facsimile – (617) 551-8820